Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 3
1948 3
1949 2
1951 2
1952 9
1953 6
1954 4
1955 8
1956 5
1957 7
1958 6
1959 4
1960 7
1961 10
1962 9
1964 5
1965 30
1966 62
1967 70
1968 100
1969 97
1970 78
1971 99
1972 103
1973 116
1974 126
1975 83
1976 78
1977 83
1978 61
1979 77
1980 51
1981 75
1982 73
1983 66
1984 86
1985 111
1986 127
1987 111
1988 144
1989 126
1990 139
1991 141
1992 152
1993 145
1994 140
1995 153
1996 117
1997 120
1998 95
1999 113
2000 105
2001 100
2002 86
2003 67
2004 79
2005 91
2006 97
2007 105
2008 97
2009 111
2010 104
2011 112
2012 103
2013 90
2014 94
2015 81
2016 97
2017 112
2018 100
2019 86
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

5,318 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
Renner UD, Oertel R, Kirch W. Renner UD, et al. Ther Drug Monit. 2005 Oct;27(5):655-65. doi: 10.1097/01.ftd.0000168293.48226.57. Ther Drug Monit. 2005. PMID: 16175141 Review.
Scopolamine Toxicity in an Elderly Patient.
Knuf KM, Spaulding FM, Stevens GJ. Knuf KM, et al. Mil Med. 2019 Dec 1;184(11-12):937-938. doi: 10.1093/milmed/usz086. Mil Med. 2019. PMID: 31004425
Scopolamine and depression: a role for muscarinic antagonism?
Hasselmann H. Hasselmann H. CNS Neurol Disord Drug Targets. 2014;13(4):673-83. doi: 10.2174/1871527313666140618105710. CNS Neurol Disord Drug Targets. 2014. PMID: 24938776 Review.
Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers.
Bukala BR, Browning M, Cowen PJ, Harmer CJ, Murphy SE. Bukala BR, et al. J Psychopharmacol. 2019 Feb;33(2):255-257. doi: 10.1177/0269881118817161. Epub 2018 Dec 11. J Psychopharmacol. 2019. PMID: 30526264 Clinical Trial.
Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
Nachum Z, Shupak A, Gordon CR. Nachum Z, et al. Clin Pharmacokinet. 2006;45(6):543-66. doi: 10.2165/00003088-200645060-00001. Clin Pharmacokinet. 2006. PMID: 16719539 Review.
Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
Parrott AC. Parrott AC. Aviat Space Environ Med. 1989 Jan;60(1):1-9. Aviat Space Environ Med. 1989. PMID: 2647072 Review.
Main Plant Extracts' Active Properties Effective on Scopolamine-Induced Memory Loss.
Balmus IM, Ciobica A. Balmus IM, et al. Am J Alzheimers Dis Other Demen. 2017 Nov;32(7):418-428. doi: 10.1177/1533317517715906. Epub 2017 Jun 23. Am J Alzheimers Dis Other Demen. 2017. PMID: 28643520 Free article. Review.
Scopolamine bioavailability in combined oral and transdermal delivery.
Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I, Lavon H, Eynan M, Dachir S, Levy A. Nachum Z, et al. J Pharmacol Exp Ther. 2001 Jan;296(1):121-3. J Pharmacol Exp Ther. 2001. PMID: 11123371 Clinical Trial.
Safety of double-dose transdermal scopolamine.
Bar R, Gil A, Tal D. Bar R, et al. Pharmacotherapy. 2009 Sep;29(9):1082-8. doi: 10.1592/phco.29.9.1082. Pharmacotherapy. 2009. PMID: 19698013 Clinical Trial.
Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report.
Goto T, Kato M, Matsumura Y, Omata N, Yoshida M, Watanabe K, Takahashi T, Higashima M, Wada Y. Goto T, et al. J Clin Psychopharmacol. 2017 Feb;37(1):106-107. doi: 10.1097/JCP.0000000000000613. J Clin Psychopharmacol. 2017. PMID: 27846048 No abstract available.
5,318 results
Jump to page
Feedback